Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide
1998

Enhancing Growth Inhibition of Prostate Cancer Cells

Sample size: 3 publication Evidence: moderate

Author Information

Author(s): MJ Campbell, M Dawson, HP Koeffler

Primary Institution: Cedars-Sinai Medical Center/UCLA School of Medicine

Hypothesis

In hormonally insensitive prostate cancer cells, Bcl-2 may play another role in promoting cell growth, and its inhibition combined with retinoids could provide a novel therapeutic approach.

Conclusion

The combination of Bcl-2 antisense oligonucleotides and the synthetic retinoid 2-HPR significantly inhibited the growth of DU-145 prostate cancer cells without inducing apoptosis.

Supporting Evidence

  • Cell growth was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control.
  • Inhibition was significantly enhanced when combined with the synthetic retinoid 2-HPR.
  • Treatment with antisense oligonucleotides resulted in a 46% reduction in Bcl-2 protein expression.

Takeaway

Researchers found that a special treatment can slow down the growth of prostate cancer cells, but it doesn't make the cells die like they expected.

Methodology

The study used DU-145 prostate cancer cells and tested the effects of antisense Bcl-2 oligonucleotides alone and in combination with retinoids on cell growth and apoptosis.

Limitations

The study did not demonstrate increased apoptosis despite significant growth inhibition.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication